L3VLUP
ProSign in

TFX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TFXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TFX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterTFXLLY
Q3 202012 holders, $3.7bn33 holders, $14.1bn
Q4 202012 holders, $4.5bn29 holders, $17.3bn
Q1 20219 holders, $4.5bn24 holders, $23.0bn
Q2 202110 holders, $4.8bn24 holders, $27.8bn
Q3 202111 holders, $4.9bn31 holders, $29.9bn
Q4 202115 holders, $4.3bn31 holders, $34.7bn
Q1 202213 holders, $4.8bn24 holders, $35.3bn
Q2 202213 holders, $3.4bn33 holders, $42.7bn
Q3 202212 holders, $1.5bn31 holders, $43.4bn
Q4 202210 holders, $1.8bn31 holders, $46.6bn
Q1 20239 holders, $2.1bn33 holders, $44.3bn
Q2 20238 holders, $2.2bn37 holders, $59.6bn
Q3 202311 holders, $1.9bn44 holders, $67.6bn
Q4 20238 holders, $2.5bn45 holders, $73.6bn
Q1 20246 holders, $2.2bn41 holders, $95.3bn
Q2 202416 holders, $2.1bn43 holders, $110bn
Q3 202412 holders, $2.1bn45 holders, $107bn
Q4 202414 holders, $1.3bn46 holders, $93.9bn
Q1 202516 holders, $1.0bn42 holders, $98.4bn
Q2 202510 holders, $742m43 holders, $93.2bn
Q3 20259 holders, $1.0bn39 holders, $86.7bn
Q4 20259 holders, $989m41 holders, $123bn
Q1 202610 holders, $1.0bn39 holders, $106bn
Q2 20269 holders, $1.2bn44 holders, $132bn
TFX

Teleflex Inc

Holders
10
Reported value
$1.0bn
Buyers
16
Sellers
16

Breadth 0 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TFX (5)

Balyasny Asset Management LLC, Baupost Group LLC, Freestone Grove Partners LP, Moore Capital Management LP, Quantbot Technologies LP

Only LLY (34)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Harris Associates LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, and 9 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →